Satavaptan

DB14923InvestigationalSmall molecule

Satavaptan is under investigation in clinical trial NCT00359437 (Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver).

Mechanism: Pharmacologically active on Vasopressin V2 receptor
Curator reviewed
Formula / weight: C₃₃H₄₅N₃O₈S · 643.8 g/mol (avg)

Resolves to

Compound

UNIIAJS8S3P31HCAS185913-78-4

Structure

InChIKeyQKXJWFOKVQWEDZ-VCCCEUOBSA-NSMILESCCOC1=CC=C2N(C(=O)[C@@]3(CC[C@@H](CC3)OCCN3CCOCC3)C2=C1)S(=O)(=O)C1=CC=C(C=C1OC)C(=O)NC(C)(C)C

Targets

P30518AVPR2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Satavaptan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account